Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Short-course radiation therapy Clear all
Recruiting Not applicable Interventional

Short Course Radiotherapy

NCT07147179
View directory record Official record
Conditions
Central Nervous System Cancer
Interventions
Short Course Radiotherapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer

NCT00039624
View directory record Official record
Conditions
Prostate Cancer
Interventions
Brachytherapy
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 24, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

NCT04021108
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Nivolumab 240 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

NCT04380337
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

NCT00005086
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

NCT03367715
View directory record Official record
Conditions
MGMT-unmethylated Glioblastoma (GBM), GBM
Interventions
Nivolumab, Ipilimumab, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 24, 2026, 2:41 PM EDT
Enrolling by invitation No phase listed Observational

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

NCT02040714
View directory record Official record
Conditions
Legg Calve Perthes Disease
Interventions
Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

NCT02270606
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 24, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

Hypofractionation (Radiation) Trial for Multiple Myeloma

NCT06270888
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Terminated Not applicable Interventional

Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer

NCT04139967
View directory record Official record
Conditions
Cancer, Rectal
Interventions
Short course radiation therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

NCT03778294
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 24, 2026, 2:41 PM EDT
Terminated Phase 3 Interventional Results available

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

NCT00388804
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 24, 2026, 2:41 PM EDT
Recruiting Early Phase 1 Interventional

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

NCT06693284
View directory record Official record
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
mirdametinib and vorinostat
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2Phase 3 Interventional

Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy

NCT00612443
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sham treatment, Healing Touch
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

NCT01821729
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Proton Beam Radiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

NCT04284540
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Adjuvant hypofractionation, Definitive Hypofractionation
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
70 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Not yet recruiting Not applicable Interventional

SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT

NCT07888283
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Adaptive stereotactic body radiotherapy (SBRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Not listed Not applicable Interventional

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

NCT01308905
View directory record Official record
Conditions
Neuroblastoma
Interventions
FLT-PET
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Day to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 24, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

FOLFIRINOX + RT for Pancreatic Cancer

NCT01591733
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Capecitabine, Short Course Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Recruiting Phase 2 Interventional

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

NCT07801664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Deprivation Therapy (ADT), Radiotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases

NCT02831348
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cystic Fibrosis, Pneumonia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 24, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional

Shortened Course Adjuvant Radiotherapy Following TORS

NCT05714657
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Interventions
Shortened Course Adjuvant Radiotherapy Following TORS
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 24, 2026, 2:41 PM EDT
Not yet recruiting Phase 2 Interventional

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

NCT07101666
View directory record Official record
Conditions
Gastric Cancer
Interventions
Short course radiation therapy, Standard of care neoadjuvant chemotherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 2:41 PM EDT